Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2025-09-15
2027-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A particularly relevant aspect of dysphagia is impaired swallowing of medication, referred to as medication dysphagia. This may compromise swallowing efficiency, for example when tablets or capsules remain in the oral cavity or pharynx and dissolve prematurely. Swallowing safety can also be affected, especially in cases of penetration or aspiration during medication intake.
To compensate for these difficulties, patients are often advised to swallow medication together with semi-solid substances instead of liquids. In addition, a commercially available swallowing gel has recently become accessible, designed specifically to facilitate medication intake in patients with dysphagia.
Despite its clinical relevance, medication dysphagia has rarely been investigated systematically with instrumental diagnostics. In particular, the compensatory strategies widely applied in practice have not yet been scientifically evaluated.
Objectives
This research project aims to determine the prevalence of medication dysphagia in patients with dysphagia-associated diseases and to assess the effects of different consistencies on the swallowing process. Specifically, the study will address the following questions:
What is the prevalence of medication dysphagia across different underlying diseases?
Is there an association between medication dysphagia and dysphagia for food and liquids?
How does the addition of a semi-solid vehicle affect the efficiency of medication swallowing?
How does the addition of a semi-solid vehicle affect the safety of medication swallowing?
How does the addition of a semi-solid vehicle influence subjective swallowing difficulties and swallowing-related anxiety during medication intake?
How does the use of a swallowing gel affect the efficiency of medication swallowing?
How does the use of a swallowing gel affect the safety of medication swallowing?
How does the use of a swallowing gel influence subjective swallowing difficulties and swallowing-related anxiety during medication intake?
Study Protocol
This is a prospective, multicenter interventional study. Eligible participants include patients with diseases associated with dysphagia who are scheduled for a clinically indicated Flexible Endoscopic Evaluation of Swallowing (FEES). Healthy control subjects will also be recruited for comparison.
At the University Hospital Düsseldorf, patients with neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular diseases will be included. Medication dysphagia will be assessed using FEES. Three experimental paradigms are planned:
Standard FEES with food and liquid:
In the following order: 10 cc green-colored jelly (semi-solid), 10 cc methylene-blue-dyed liquid, and a piece of white bread (\~3 × 3 × 0.5 cm, solid).
Three swallows will be tested for each bolus.
FEES assessment of medication dysphagia:
Three swallow trials will be conducted in randomized order for each of the following conditions:
1. Placebo medication with methylene-blue-dyed water.
2. Placebo medication with a semi-solid vehicle.
3. Placebo medication with the swallowing gel GLOUP®.
Subjective evaluation:
Perceived swallowing difficulty and swallowing-related anxiety will be assessed for each condition using a numerical rating scale (1-10).
Analysis
Medication dysphagia will be evaluated using a previously published and validated FEES-based classification system developed by our research group. This tool enables systematic assessment of swallowing efficiency and safety during medication intake.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
neurogenic dysphagia group
patients with neurological diseases that may lead to dysphagia
medication swallowing
Three swallow trials will be conducted in randomized order for each of the following conditions:
1. Placebo medication with methylene-blue-dyed water.
2. Placebo medication with a semi-solid vehicle.
3. Placebo medication with the swallowing gel GLOUP®.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
medication swallowing
Three swallow trials will be conducted in randomized order for each of the following conditions:
1. Placebo medication with methylene-blue-dyed water.
2. Placebo medication with a semi-solid vehicle.
3. Placebo medication with the swallowing gel GLOUP®.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Adults with a dysphagia-associated disease (neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; in other centers also ENT-related diseases), for whom FEES is clinically indicated.
Capable of providing informed consent and cognitively able to follow the study protocol.
Healthy Controls Adults without any dysphagia-associated disease (no neurovascular, neurodegenerative, neuroinflammatory, or neuromuscular disorders; no ENT-related diseases with structural abnormalities of the oropharynx or esophagus).
Capable of providing informed consent and cognitively able to follow the study protocol.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany
University Hospital Münster
Münster, North Rhine-Westphalia, Germany
Hospital Osnabrücl
Onsabrück, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bendix FEES Labeit, MD
Role: primary
Sonja Suntrup-Krüger, MD
Role: primary
Role: backup
Rainer Dziewas
Role: primary
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-2989
Identifier Type: -
Identifier Source: org_study_id